These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22164947)

  • 1. [Public financing for off-label use of drugs].
    Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
    Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label use reimbursement.
    Cohen J; Wilson A; Faden L
    Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
    Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
    Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
    Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
    Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
    Ha D; Choi Y; Kim DU; Chung KH; Lee EK
    Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Legal decisions of german supreme courts about prescription of drugs for not registered indications ("off-label-use")].
    Wetterling T
    Fortschr Neurol Psychiatr; 2004 May; 72(5):255-9. PubMed ID: 15136946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
    Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Off-label therapy from the perspective of the medical insurance service].
    Grell L; Rieger M
    Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland.
    Bending M; Hutton J; McGrath C
    Int J Technol Assess Health Care; 2012 Apr; 28(2):187-94. PubMed ID: 22559763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public Reimbursement of Prescription Drugs Used For Off-Label Indications in Ontario.
    Rawson N; Chhabra A
    J Popul Ther Clin Pharmacol; 2018 Sep; 25(2):e23-e30. PubMed ID: 30725540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Off-label therapy in rheumatology].
    Krüger K; Sieper J
    Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
    Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
    J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Off-label prescription of drugs in the statutory health insurance].
    Niederauer HH
    Gesundheitswesen; 2010 Feb; 72(2):116-9. PubMed ID: 19894208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biostatistical aspects for the use of evidence based medicine in health technology assessment.
    Freemantle N
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():31-43. PubMed ID: 18987906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
    Janzen RW; Ludwig WD;
    Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of medications: innovative prescribing or risky business?
    Martin CM
    Consult Pharm; 2010 Dec; 25(12):806-10, 813-4. PubMed ID: 21172761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.